Biotechs Gain As Wall Street Bets Big And Small On Consolidation
Executive Summary
Chiron's $1.4 bil. available for acquisitions is acting as a lightning rod for speculation as Wall Street looks to the larger biotechs to enter the buying trend started by big pharma firms.